Rubulavirus
If not vaccinated against mumps, susceptible individuals catch the disease by breathing around an infected person who has coughed or sneezed, releasing their contaminated saliva. Those who have had mumps are usually immune to future infections of the disease. Children have the highest risk of catching mumps, and it is rare for an adult to contract mumps. The incubation period for mumps can range from a couple weeks to a month, while the illness period is a few weeks. The swelling of the salivary glands is caused when the virus travels from the respiratory tract to the salivary glands and multiplies within the glands, causing the glands to swell.
Mumps vaccine
The cells used in culture, virus stocks used, and animal fluids are all screened for extraneous material as part of the vaccine production. They are grown in Medium 199 (a solution containing buffered salt, vitamins, amino acids, fetal bovine serum) with SPGA (sucrose, phosphate, glutamate, human serum albumin) and neomycin. The human albumin processing uses the Cohn cold ethanol fractionation method. Mumpsvax production as a stand-alone product ceased in 2009.Monovalent mumps vaccine (Mumpsvax) remained available in the U.S.A when MMR was introduced in the UK, replacing the MR (measles and rubella) mixed vaccine. No UK-licensed monovalent preparation was ever available. This became the subject of considerable argument at the end of the 20th century, since some parents preferred to obtain individually the components of the MMR mixture. One mumps vaccine preparation imported into the United Kingdom and unlicensed, proved to be essentially ineffective. Immunisation against mumps in the UK became routine in 1988, commencing with MMR. The Aventis-Pasteur "MMR-2" brand is usual in the UK in 2006.